Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020

Date: July 7, 2015
Pages: 193
Price:
US$ 4,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NE5571DF3C8EN
Leaflet:

Download PDF Leaflet

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020
Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The global nuclear medicine/radiopharmaceuticals market is growing due to the increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 are estimated to be the highest contributors to the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, Ra-223, I-131, and Y-90 are estimated to be the highest contributors for the nuclear medicine/radiopharmaceuticals therapeutics market in 2015.

In 2015, the diagnostics segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, by type; the SPECT segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, the beta emitters segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals therapeutics market.

In 2015, North America accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, followed by Asia-Pacific, Europe, and the Rest of the World (RoW). In the coming years, the Asia-Pacific region is expected to witness the highest growth rate for the nuclear medicine/radiopharmaceuticals market, with an emphasis on India, China, Japan, and Australia. These countries are expected to be lucrative markets for the manufacturers of radiopharmaceuticals.

The global nuclear medicine/radiopharmaceuticals market witnesses high-competitive intensity as there are several large and small firms with similar product offerings. These companies adopt various strategies (agreements, contracts, partnerships, expansions, acquisitions, market development, new product launches, marketing and promotional activities, technological enhancements, and website launches) to increase their market shares and to establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the nuclear medicine/radiopharmaceuticals market. The report analyzes the nuclear medicine/radiopharmaceuticals market by type, and application, and procedural volume
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the nuclear medicine/radiopharmaceuticals market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various nuclear medicine/radiopharmaceuticals technologies across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the nuclear medicine/radiopharmaceuticals market
  • Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine/radiopharmaceuticals market
1 INTRODUCTION

1.1 OBJECTIVES OF STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH METHODOLOGY STEPS
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
  2.2.1 SECONDARY RESEARCH
  2.2.2 PRIMARY RESEARCH
  2.2.3 KEY INDUSTRY INSIGHTS
2.3 KEY DATA FROM PRIMARY SOURCES
2.4 KEY INSIGHTS FROM PRIMARY SOURCES
2.5 MARKET SIZE ESTIMATION METHODOLOGY
2.6 RESEARCH DESIGN
2.7 MARKET DATA VALIDATION AND TRIANGULATION
2.8 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION

4 PREMIUM INSIGHTS

4.1 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
4.2 SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTICS MARKET, BY REGION AND APPLICATION
4.3 REGIONAL SNAPSHOT OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
4.4 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020)

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 DRIVERS
    5.2.1.1 Increasing preference for SPECT and PET scans
    5.2.1.2 Advances in radiotracers
    5.2.1.3 Alpha radio immunotherapy-based targeted cancer treatment
    5.2.1.4 Increasing incidence of cancer and cardiac ailments
  5.2.2 RESTRAINTS
    5.2.2.1 Shorter half-life of radiopharmaceuticals restricts its usage
    5.2.2.2 Stringent regulatory and GMP guidelines
    5.2.2.3 Competition from conventional diagnostic procedures
  5.2.3 OPPORTUNITIES
    5.2.3.1 Potential radioisotopes in the pipeline
    5.2.3.2 High demand in emerging markets
    5.2.3.3 Neurological applications
  5.2.4 THREAT
    5.2.4.1 Shutdown of nuclear reactors

6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

6.1 INTRODUCTION
6.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  6.2.1 SPECT RADIOPHARMACEUTICALS
    6.2.1.1 Technetium-99m (Tc-99m)
    6.2.1.2 Thallium-201 (Tl-201)
    6.2.1.3 Gallium-67 (Ga-67)
    6.2.1.4 Iodine (I-123)
    6.2.1.5 Others
  6.2.2 PET RADIOPHARMACEUTICALS
    6.2.2.1 Fluorine-18 (F-18)
    6.2.2.2 Rubidium-82 (Rb-82)
    6.2.2.3 Others
6.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  6.3.1 BETA EMITTERS
    6.3.1.1 Iodine-131 (I-131)
    6.3.1.2 Yttrium-90 (Y-90)
    6.3.1.3 Samarium-153 (Sm-153)
    6.3.1.4 Rhenium-186 (Re-186)
    6.3.1.5 Lutetium-177 (Lu-177)
    6.3.1.6 Others
  6.3.2 ALPHA EMITTERS
    6.3.2.1 Radium-223 (Ra-223)
  6.3.3 BRACHYTHERAPY
    6.3.3.1 Cesium-131
    6.3.3.2 Iodine-125
    6.3.3.3 Palladium-103
    6.3.3.4 Iridium-192
    6.3.3.5 Others

7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

7.1 INTRODUCTION
7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  7.2.1 SPECT RADIOPHARMACEUTICALS
  7.2.2 PET RADIOPHARMACEUTICALS
7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  7.3.1 BETA EMITTERS
  7.3.2 ALPHA EMITTERS
  7.3.3 BRACHYTHERAPY

8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
  8.2.1 SPECT APPLICATIONS
    8.2.1.1 Cardiology
    8.2.1.2 Lymphoma
    8.2.1.3 Neurology
    8.2.1.4 Thyroid
    8.2.1.5 Other Diagnostic Applications
  8.2.2 PET APPLICATIONS
    8.2.2.1 Oncology
    8.2.2.2 Cardiology
    8.2.2.3 Neurology
    8.2.2.4 Other PET Applications
8.3 THERAPEUTIC APPLICATIONS
  8.3.1 THYROID
  8.3.2 BONE METASTASIS
  8.3.3 LYMPHOMA
  8.3.4 ENDOCRINE TUMORS
  8.3.5 OTHER THERAPEUTIC APPLICATIONS

9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION

9.1 INTRODUCTION
9.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  9.2.1 NORTH AMERICA
    9.2.1.1 DEVELOPMENT OF MO-99 PRODUCTION FACILITIES IN THE U.S.
    9.2.1.2 FDA APPROVALS OF NEW RADIOPHARMACEUTICALS
    9.2.1.3 EXTENSION OF OPERATIONS IN THE CANADIAN NATIONAL RESEARCH UNIVERSAL (NRU) REACTOR
    9.2.1.4 DEVELOPMENT OF ALTERNATIVE MEDICAL ISOTOPE TECHNOLOGIES IN CANADA
  9.2.2 EUROPE
    9.2.2.1 INCREASING ACCEPTABILITY OF 18F-FDG PET-CT IN THE U.K.
    9.2.2.2 SHUTDOWN OF FRENCH NUCLEAR REACTOR
    9.2.2.3 NEW IRRADIATION FACILITY IN GERMANY
  9.2.3 ASIA-PACIFIC
    9.2.3.1 INTRODUCTION OF NEW COST-EFFECTIVE TC-99 GENERATORS IN INDIA
    9.2.3.2 HIGH INCIDENCE OF CANCER AND CARDIOVASCULAR DISEASE IN CHINA
    9.2.3.3 INCREASING MO-99 PRODUCTION IN AUSTRALIA
    9.2.3.4 INITIATIVES TO PROMOTE HEALTH IN ASIA-PACIFIC
  9.2.4 REST OF THE WORLD
    9.2.4.1 DEVELOPMENT OF MULTIPURPOSE RESEARCH REACTOR IN BRAZIL
    9.2.4.2 ARGENTINA’S INCREASING IRRADIATION CAPACITY
    9.2.4.3 CONVERSION OF THE SAFARI 1 REACTOR, FROM HEU-BASED MO-99 PRODUCTION TO LEU
9.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
  9.3.1 NORTH AMERICA
    9.3.1.1 FDA approval for alpha emitters in the U.S.
    9.3.1.2 Therapeutic nuclear medicine, an alternative choice of treatment in oncology
    9.3.1.3 Increase in the incidence of thyroid cancer
    9.3.1.4 Expertise in isotope production
    9.3.1.5 Government initiatives
    9.3.1.6 High incidence of cancer
  9.3.2 EUROPE
    9.3.2.1 Increasing awareness of radioisotope therapy in the U.K.
    9.3.2.2 Adverse reactions to radiopharmaceuticals in France
    9.3.2.3 Radionuklidtherapeutika—research program conducted in Germany
    9.3.2.4 Russia, an upcoming country for radionuclide therapy
  9.3.3 ASIA-PACIFIC
    9.3.3.1 Increased production of radiopharmaceuticals for therapeutic purposes in India
    9.3.3.2 Aging population and increasing cancer incidence
    9.3.3.3 Approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA)
  9.3.4 REST OF THE WORLD(ROW)
    9.3.4.1 Growing aging population
    9.3.4.2 Increase in cancer incidences

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW
10.2 MARKET SHARE ANALYSIS
  10.2.1 INTRODUCTION
  10.2.2 CARDINAL HEALTH, INC.
  10.2.3 MALLINCKRODT PLC
  10.2.4 GE HEALTHCARE
  10.2.5 LANTHEUS MEDICAL IMAGING, INC.
  10.2.6 BAYER HEALTHCARE
10.3 COMPETITIVE SITUATION AND TRENDS
  10.3.1 INTRODUCTION
  10.3.2 AGREEMENTS, CONTRACTS, AND PARTNERSHIPS
  10.3.3 ACQUISITIONS
  10.3.4 MARKET DEVELOPMENT
  10.3.5 EXPANSION
  10.3.6 NEW PRODUCT LAUNCHES
  10.3.7 OTHERS

11 COMPANY PROFILES

11.1 INTRODUCTION
11.2 CARDINAL HEALTH, INC.
11.3 MALLINCKRODT PLC
11.4 GE HEALTHCARE
11.5 LANTHEUS MEDICAL IMAGING, INC.
11.6 BAYER HEALTHCARE
11.7 BRACCO IMAGING S.P.A
11.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS
11.9 NORDION, INC.
11.10 ADVANCED ACCELERATOR APPLICATIONS S.A.
11.11 IBA MOLECULAR IMAGING

*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

12 APPENDIX

12.1 DISCUSSION GUIDE
12.2 COMPANY DEVELOPMENTS (2012–2015)
  12.2.1 CARDINAL HEALTH, INC.
  12.2.2 BAYER HEALTHCARE
12.3 AVAILABLE CUSTOMIZATIONS
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.5 RELATED REPORTS

LIST OF TABLES

Table 1 ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 2 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE NUCLEAR MEDICINE MARKET
Table 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE NUCLEAR MEDICINE MARKET
Table 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THIS MARKET
Table 5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC SEGMENT, BY REGION, 2013-2020 ($MILLION)
Table 7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION)
Table 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY ISOTOPE TYPE, 2013-2020 ($MILLION)
Table 10 GLOBAL SPECT MARKET SIZE FOR TECHNETIUM-99M ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 11 GLOBAL SPECT MARKET SIZE FOR THALLIUM-201 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 12 GLOBAL SPECT MARKET SIZE FOR GALLIUM-67 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 13 GLOBAL SPECT MARKET SIZE FOR IODINE-123 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 14 GLOBAL SPECT MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 15 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 16 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY ISOTOPE, 2013-2020 ($MILLION)
Table 17 GLOBAL PET MARKET SIZE FOR FLUORINE-18 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 18 GLOBAL PET MARKET SIZE FOR RUBIDIUM-82 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 19 GLOBAL PET ISOTOPES MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 20 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 21 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION)
Table 22 GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
Table 23 GLOBAL BETA EMITTERS MARKET SIZE, BY ISOTOPE, 2013-2020 ($MILLION)
Table 24 GLOBAL BETA EMITTERS MARKET SIZE FOR IODINE-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 25 GLOBAL BETA EMITTERS MARKET SIZE FOR YTTRIUM-90 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 26 GLOBAL BETA EMITTERS MARKET SIZE FOR SAMARIUM-153 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 27 GLOBAL BETA EMITTERS MARKET SIZE FOR RHENIUM-186 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 28 GLOBAL BETA EMITTERS MARKET SIZE FOR LUTETIUM-177 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 29 GLOBAL BETA EMITTERS MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 30 GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
Table 31 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY REGION, 2013-2020 ($MILLION)
Table 32 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY ISOTOPES, 2013-2020 ($MILLION)
Table 33 GLOBAL BRACHYTHERAPY MARKET SIZE FOR CESIUM-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 34 GLOBAL BRACHYTHERAPY MARKET SIZE FOR IODINE-125 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 35 GLOBAL BRACHYTHERAPY MARKET SIZE FOR PALLADIUM-103 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 36 GLOBAL BRACHYTHERAPY MARKET SIZE FOR IRIDIUM-192 ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 37 GLOBAL BRACHYTHERAPY MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION)
Table 38 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND)
Table 39 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND)
Table 40 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND)
Table 41 NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND)
Table 42 NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND)
Table 43 NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND)
Table 44 NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND)
Table 45 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND)
Table 46 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND)
Table 47 NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND)
Table 48 NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013–2020 (THOUSAND)
Table 49 NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND)
Table 50 NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013–2020 (THOUSAND)
Table 51 NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND)
Table 52 NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND)
Table 53 SEGMENTATION OF NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE
Table 54 NUCLEAR MEDICINE/RADIOPHAMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 55 NUCLEAR MEDICINE/RADIOPHAMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 ($MILLION)
Table 56 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 57 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 58 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 59 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 60 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 61 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION OF PET, BY APPLICATION
Table 62 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 63 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 ($MILLION)
Table 64 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 65 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 66 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 67 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 68 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 69 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013–2020($MILLION)
Table 70 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 71 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 72 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 73 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE TUMOR THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 74 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION)
Table 75 GLOBAL NUCLEAR MEDICINE /RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2013-2020 ($MILLION)
Table 76 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 77 NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 78 NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 79 NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
Table 80 NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
Table 81 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 82 EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 83 EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 84 EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
Table 85 EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
Table 86 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 87 ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 88 ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 89 ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
Table 90 ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
Table 91 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 92 ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 93 ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 94 ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
Table 95 ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)
Table 96 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 97 NORTH AMERICA: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 98 NORTH AMERICA: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 99 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 100 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 101 EUROPE: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 102 EUROPE: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 103 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION)
Table 104 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 105 ASIA-PACIFIC: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 106 ASIA-PACIFIC: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 107 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION)
Table 108 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION)
Table 109 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 110 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION)
Table 111 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION)

LIST OF FIGURES

Figure 1 NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION
Figure 2 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS
Figure 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 DIAGNOSTICS MARKET TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020
Figure 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTICS MARKET SHARE, BY TYPE, 2015–2020
Figure 9 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Figure 10 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS, 2015–2020
Figure 11 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH
Figure 12 NORTH AMERICA DOMINATES THE SPECT NUCLEAR MEDICINE DIAGNOSTICS MARKET IN 2015
Figure 13 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 14 DIAGNOSTICS SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
Figure 15 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, CHALLENGES, & OPPORTUNITIES
Figure 16 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE
Figure 17 THERAPEUTIC SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.5%
Figure 18 PET SEGMENT TO GROW AT THE HIGHEST CAGR OF 11.7% DURING THE FORECAST PERIOD
Figure 19 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 17.3% DURING THE FORECAST PERIOD
Figure 20 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 9.4% DURING THE FORECAST PERIOD
Figure 21 THE NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.4% DURING THE FORECAST PERIOD
Figure 22 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 13.1% DURING THE FORECAST PERIOD
Figure 23 THE NEUROLOGY APPLICATION SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR OF 12.9% DURING THE FORECAST PERIOD
Figure 24 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC APPLICATIONS MARKET SEGMENTATION, BY TYPE
Figure 25 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 12.2% DURING THE FORECAST PERIOD
Figure 26 THE ENDOCRINE TUMORS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR OF 11.3% DURING THE FORECAST PERIOD
Figure 27 NORTH AMERICA COMMANDS LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015
Figure 28 NORTH AMERICA IS LIKELY TO WITNESS A CAGR OF 8.1% DURING THE FORECAST PERIOD
Figure 29 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET TO GROW AT A CAGR OF 7.1% DURING THE FORECAST PERIOD
Figure 30 ASIA-PACIFIC IS LIKELY TO WITNESS A CAGR OF 10.1% DURING THE FORECAST PERIOD
Figure 31 ROW NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET IS LIKELY TO GROW AT A CAGR OF 9% IN THE FORCAST PERIOD
Figure 32 NORTH AMERICA IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET IN 2015
Figure 33 NORTH AMERICA TO WITNESS A CAGR OF 10% IN THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET DURING THE FORECAST PERIOD
Figure 34 EUROPE IS LIKELY TO WITNESS A CAGR OF 9.8% DURING THE FORECAST PERIOD
Figure 35 ASIA-PACIFIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET TO GROW AT A CAGR OF 12.2% DURING THE FORECAST PERIOD
Figure 36 THE GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET IN ROW IS EXPECTED TO GROW AT A CAGR OF 8.7% DURING THE FORECAST PERIOD
Figure 37 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
Figure 38 STRATEGIES ADOPTED BY KEY PLAYERS OVER THE LAST THREE YEARS (2012-2015)
Figure 39 BATTLE FOR MARKET SHARE: AGREEMENTS/CONTRACTS/PARTNERSHIPS WAS THE KEY STRATEGY (2012 -2015)
Figure 40 AGREEMENTS, CONTRACTS, AND PARTNERSHIPS, 2012-2015
Figure 41 ACQUISITIONS, 2012-2015
Figure 42 MARKET DEVELOPMENT, 2012-2015
Figure 43 EXPANSIONS, 2012-2015
Figure 44 NEW PRODUCT LAUNCHES, 2012-2015
Figure 45 OTHER STRATEGIES, 2012-2015
Figure 46 GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET
Figure 47 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
Figure 48 MALLINCKRODT PLC: COMPANY SNAPSHOT
Figure 49 GE HEALTHCARE: COMPANY SNAPSHOT
Figure 50 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT
Figure 51 BAYER HEALTHCARE: COMPANY SNAPSHOT
Figure 52 NORDION, INC.: COMPANY SNAPSHOT
Figure 53 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT
Skip to top


Ask Your Question

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: